More alemtuzumab news!

BBC: Multiple sclerosis: New drug ‘most effective’…



University of Cambridge news: New MS drug proves effective where others have failed….


Nature News Blog: MS treatment shows success in clinical trials……


Lancet editorial: Alemtuzumab for multiple sclerosis……


Independent article: New MS wonder drug may be too costly to use…..


Reuters: Sanofi draws fire over cost of MS drug Lemtrada…..

Sanofi-Genzyme press release:




CoI: I am a co-author on the CARE-MS1 study, the principal investigator on the CARE-MS1 & 2 studies at Barts Health and have received consultancy and honorarium payments from Genzyme and Sanofi, in relation to alemtuzumab.

7 thoughts on “More alemtuzumab news!”

  1. Three posts about Lemtrada. No doubt you are carefully constructing consent. Some call it hype.

  2. I don't get it!Why is it better than Tysabri considering that we have now a good idea of what the risks of Tysabri are?Why is a ¬70% cut in relapse rate for Campath so much better than Tysabri's 70% ?I have never agreed with VV but feel that he just put his finger on the right button: Too much unnecessary hype.

    1. I'm not sure, but was the reduction in Tysabri's relapse rate measured against a placebo, whereas alemtuzumab's was measured against rebif? It also seems to be better re accruing disability.Maybe more risks with alemtuzumab will emerge later, but the mayor risks with tysabri are well-documented- PML if you're JCVe+, and if you decide to come off it IRIS, and now these recent cases of fulminant MS in MSers who switched to fingolimod.I'd rather go with the risks of alemtuzumab, but it's a personal decision.I don't even bother with VVs comments- we all know his agenda.

    2. Two study results and lots of press coverage, so 3 posts are not excessive. And many of us are very interested in alemtuzumab.

    3. Thanks Roshni but I understand that it's 70% for both drugs like-for-like.PML on the side, what is all this hype about?Is there any proven quantifiable disability progression impact v.s. Tysabri?

    4. It is not better than natalizumab. Just another option. Horses, for courses. Some will prefer induction therapy and the potential of a cure others sticky plaster and the wolves at at the door. It is a bout choice.

  3. Prof G,I'm surprised by the results as I know three people from the Phase II trial who are relapse free after 7 years i.e. no relapses since their first infusion.In all three cases, they saw some degree of improvement following their first infusion. However, they all have some degree of disability (minor) e.g. stiff leg muscles. All three work full time and consider themselves lucky to have received Campath (as it was then called). My question – will there likely be future treatments which might address some of their remaining decifits (one has stiff knees so can't run well). I've seen the term irreversible disability, but is it really so i.e. no chance of any futher improvement / reduction in deficits?

Leave a Reply

%d bloggers like this: